Fluorescent proteins have become an important tool in cancer biology.
Watch the video to learn how researchers dissect the biology of cancer in vivo.
Fluorescent proteins (FPs) have become an important tool in cancer biology, enabling researchers to dissect the biology of cancer in vivo. By linking them to key proteins, FPs enables the visualization of important derangements that facilitate cancer progression and allow for monitoring of tumor-host interactions, stromal invasion, metastasis and angiogenesis. Using real-time optical imagers coupled with green fluorescent protein (GFP) and other colored proteins, metastasis can be observed at the subcellular, cellular and tissue levels. Thus, optical imaging using fluorescent proteins is a powerful technology for studying the critical steps in the initiation and progression of metastasis within an in vivo model. In this webinar, we will discuss several important applications that highlight the usefulness of FPs, including:
Intravascular and lymphatic cell trafficking
Cancer cell seeding of organs
Monitoring of anti-tumor and anti-metastasis therapy
Robert M. Hoffman, Ph.D., has been a faculty member at the University of California San Diego since 1979 and has served as a Professor in the Department of Surgery at the same institution since 1995. In 1984, Dr. Hoffman founded AntiCancer, Inc., a biotechnology company in the San Diego area devoted to developing tools and protocols to study cancer in vivo. Dr. Hoffman completed his B.A. in Biology at the State University of New York, Buffalo, NY, and completed his Ph.D. of Biology at Harvard University in Cambridge, MA. He completed his postdoctoral training at Harvard University, Department of Biology at the Harvard Medical School (1971-1973) followed by Massachusetts General Hospital (1973-1975) and the Shemyakin Institute of Bioorganic Chemistry, Moscow, as a National Academy of Sciences exchange fellow (1976-1977). Dr. Hoffman has over 600 peer-reviewed publications and has been recognized for his achievements in the field of cancer research through numerous awards and honors. He has served on numerous review and editorial boards including the National Cancer Institute and Anticancer Research, respectively. Dr. Hoffman and his team has pioneered the use of fluorescent proteins for in vivo imaging, was the first to image the tumor microenvironment, was one of the first to use orthotopic models to demonstrate the importance of tumor-associated stromal cells in metastasis, and co-discovered the formation of angiogenesis from cancer cells.
Dr. Tony Sanchez is an in vivo applications specialist for UVP, LLC, a Southern California based bioimaging company. Tony is a graduate of Keck Graduate Institute (2010-2011) following his Doctorate of Medicine at Rush Medical College, Chicago, IL (2005), and Bachelor of Science, Biochemistry, from the University of IL, Urbana-Champaign, IL (1999). Tony completed a research fellowship in neuromodulation of respiration at the Medical College of Wisconsin (2006-2007) and was involved in human trial in clinical oncology at the University of California, Irvine (2007-2010).